Anti-HRSV Fusion Protein Reference Antibody (Motavizumab, RUO)

SKU: VK421036

Size:100ug

Description:Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations. Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions).

Host species:Humanized

Tested applications:

Species reactivity:HRSV-A

Form:Liquid

Storage buffer:0.01M PBS, pH 7.4.

Purity:>95% purity as determined by SDS-PAGE.

Clonality:Monoclonal

Isotype:IgG1, kappa

Applications:ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Target:F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

Purification:Protein A/G purified from cell culture supernatant.

Endotoxin level:Please contact us for this information.

Expression system:Mammalian Cells

Accession:P03420

Stability and Storage:Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

Reconstitution:

Background:

Alternative Names:MEDI-524, NUMAX, NISTmAb, CR9503, 677010-34-3

Clone ID:

Species:

Note:For research use only. Not suitable for clinical or therapeutic use.